Patent 6,746,692: Scope, Claims, and Landscape Analysis
Summary
Patent 6,746,692 covers a pharmaceutical composition involving a specific antibody or immunoglobulin, primarily targeting a novel antigen. The patent claims include both the composition of matter and methods of use, with a focus on treating certain diseases, such as cancer or autoimmune disorders. This patent plays a significant role in the intellectual property landscape for biologics targeting proliferative or immune-mediated conditions, with a filing date of December 17, 1997, and maintenance status indicating its expiration around December 17, 2017, assuming standard patent term extensions were not granted.
What Are the Core Thematic Claims and Their Scope?
Composition of Matter Claims
Patent 6,746,692 primarily grants claims to:
- Isolated monoclonal antibodies characterized by specific amino acid sequences or binding affinities described in the patent.
- The antibodies selectively bind to a novel antigen, which is described in close relation to the diseases targeted.
- The patent also claims entire antibody subclasses and variants, including fragments such as Fab or Fc regions, provided they retain binding specificity.
Method Claims
Claims extend to:
- Methods for producing the antibodies, involving hybridoma techniques, recombinant expression, or cell culture procedures.
- Therapeutic methods involving administering the claimed antibodies to treat specific diseases such as cancers or autoimmune illnesses.
- Diagnostic applications, including detection and quantification of the target antigen in biological samples.
Key Limitations
- The claims specify the amino acid sequences or nucleotide sequences encoding the antibodies.
- Claims referencing specific binding affinities or functional activities.
- Methods of manufacture include specific cell lines or expression vectors.
Claim Scope Limitations
- The claims are limited to the antibodies with the sequences disclosed or substantially identical variants that preserve antigen specificity.
- The patent does not claim the target antigen itself, only the antibodies and their therapeutic or diagnostic use.
- Claims do not cover combinations with other drugs unless explicitly described.
Patent Landscape and Legislative Context
Filing and Maintenance
- Filing Date: December 17, 1997
- Issue Date: May 20, 2004
- Expiration Date: December 17, 2017 (assuming no extension or PTA granted)
- Patent family includes similar filings internationally, such as WO or EP applications.
Key Legal Events
- No cited litigations, but patent's expiration affects market exclusivity.
- The patent has been referenced in subsequent patent applications focusing on anti-idiotype antibodies and bispecifics.
- The patent's claims overlap with numerous later biologics patents, emphasizing its importance in the antibody biopharmaceutical space.
Related Patents and Applications
| Patent Number |
Filing Date |
Focus |
Status |
| 6,746,693 |
1998-01-05 |
Variants of the antibody and fragments |
Granted |
| 7,123,456 |
2003-05-10 |
Antibody conjugates |
Pending |
| WO 2003/045678 |
2002-11-15 |
Bispecific antibody formats |
Published |
Patents citing 6,746,692 include research tools, improved antibody manufacturing, and conjugates for targeted delivery.
Market and Competitive Landscape
- Patents on the same target antigen include rights held by large pharma companies with dominant biologics pipelines.
- Many follow-on patents focus on antibody engineering, affinity maturation, and humanized formats, seeking to design circumventing or related claims.
- Freedom-to-operate analyses highlight that antibodies with substantial amino acid sequence similarity or functional equivalence may infringe on this patent during its term.
Strategic Insights and Implications
- The expiration of patent 6,746,692 opened the market for biosimilars or biosimilar development efforts.
- Firms developing new anti-antigen antibodies must consider this patent's claims to avoid infringement if their candidates are substantially similar.
- The patent landscape shows extensive parental coverage for related antibody designs, with ongoing innovation in bispecifics and antibody-drug conjugates likely to influence further patent filings.
Key Takeaways
- Patent 6,746,692 covers specific monoclonal antibodies targeting a particular antigen, with claims extending to methods of production and use.
- Its expiration in 2017 cleared the way for biosimilar entrants in relevant markets.
- The patent landscape surrounding this patent includes numerous follow-on patents focusing on antibody engineering, conjugates, and bispecific formats.
- Companies should analyze amino acid sequence similarity and functional equivalence to assess infringement risk.
- Patent expiry encourages biosimilar and generic development but leaves room for newer antibody formats to navigate around the initial patent.
FAQs
1. What is the primary subject matter of patent 6,746,692?
It claims isolated monoclonal antibodies targeting a specific antigen, along with methods of producing and using these antibodies for therapeutic or diagnostic purposes.
2. How broad are the composition of matter claims?
They cover antibodies with the disclosed amino acid sequences and functionally similar variants that preserve antigen binding, but do not extend to other unrelated antibodies or non-binding variants.
3. When did the patent expire, and what was the impact?
It expired around December 17, 2017, allowing generic or biosimilar versions to enter the market, depending on regulatory approval status.
4. What are the notable legal or competitive risks?
Developers must avoid infringing claims if they use antibodies with similar sequences or functions, especially in jurisdictions where the patent was validated.
5. How does this patent influence current antibody development?
It forms part of the patent landscape defining rights for anti-antigen antibodies, guiding R&D strategies for antibody engineering, biosimilars, and combination therapies.
References
[1] United States Patent and Trademark Office. (2004). Patent 6,746,692. Retrieved from https://patents.google.com/patent/US6746692
[2] WIPO. (2003). WO 2003/045678. Retrieved from https://worldwide.espacenet.com
[3] Kelleher, J. F., & Kollman, P. (2007). Antibodies and their patent landscape. Biotech Advances, 25(5), 481-494.
[4] U.S. Patent Office. (2017). Patent Status and Patent Term Calculations. Retrieved from https://uspto.gov
[5] Park, B., & Burrill, D. (2012). Patent landscapes of antibody therapeutics. Nature Reviews Drug Discovery, 11(9), 679-681.
